In breast cancer, the type II TGF-β receptor TβRII is directly deubiquitinated and stabilized by USP8, which increases the expression of TβRII in the plasma membrane as well as tumor-derived extracellular vesicles (TEVs). Here, TGFBR2 is linked to neoplasm.